It is an international innovative biotechnology high-tech company focuses on the research and development of new tumor drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 7, 2022 | Series C | ¥330M | 1 | Houji Ziben | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Houji Ziben | Yes | Series C |